### 04/12/2016 503778521

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1

EPAS ID: PAT3825167 Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

### **CONVEYING PARTY DATA**

Name	Execution Date
KWANGHO LEE	10/15/2014
DEQIANG NIU	11/24/2014
MATTHEW F. BAEVSKY	03/14/2015

### **RECEIVING PARTY DATA**

Name:	CELGENE AVILOMICS RESEARCH, INC.
Street Address:	45 WIGGINS AVENUE
City:	BEDFORD
State/Country:	MASSACHUSETTS
Postal Code:	01730

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	14448578

### CORRESPONDENCE DATA

Fax Number: (617)502-5002

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 617-248-5000

Email: vhughes@choate.com

CHOATE, HALL & STEWART LLP **Correspondent Name:** Address Line 1: TWO INTERNATIONAL PLACE

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	2007878-0433
NAME OF SUBMITTER:	KRISTEN C. BUTEAU
SIGNATURE:	/Kristen C. Buteau/
DATE SIGNED:	04/12/2016

### **Total Attachments: 6**

source=2007878-0433-Assignment#page1.tif source=2007878-0433-Assignment#page2.tif source=2007878-0433-Assignment#page3.tif source=2007878-0433-Assignment#page4.tif

> **PATENT REEL: 038249 FRAME: 0775** 503778521

source=2007878-0433-Assignment#page5.tif source=2007878-0433-Assignment#page6.tif

PATENT REEL: 038249 FRAME: 0776

Attorney Docket No: 2007878-0433

### COMBINED JOINT ASSIGNMENT & DECLARATION

### A. ASSIGNMENT

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
1. Kwangho Lee	Daejeon, Korea
2. Deqiang Niu	Lexington, MA
3. Matthew F. Baevsky	Northborough, MA

### Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

# MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF; and □ prepared for filing in the United States Patent and Trademark Office; or □ identified by United States Application Serial No. 14/448,578 filed in the United States Patent and Trademark Office on July 31, 2014; and □ identified by International Patent Application No. Serial No. filed on Filing Date; and □ is also aware of the following priority applications: Serial No.: 13/291,706; Filed: November 8, 2011 Serial No.: 61/534,330; Filed: September 13, 2011

WHEREAS Celgene Avilomics Research, Inc. (hereinafter "ASSIGNEE"), having a usual place of business at 45 Wiggins Avenue, Bedford, MA, 01730, desires to acquire or confirm an interest therein;

Serial No.: 61/412,388; Filed: November 10, 2010

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, I have sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. My

Page 1 of 6

2007878-0433

sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including to divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by me had this sale, assignment and transfer not been made:

- AND, I hereby acknowledge that this Assignment, being of my entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;
- AND, I hereby further agree for myself and my executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts I know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;
- AND, I further hereby authorize ASSIGNEE or its attorneys or agents to insert the correct serial number(s) and/or filing date(s) into this assignment document, if appropriate;
- AND, I hereby appoint ASSIGNEE as my common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;
- AND, I hereby request the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;
- AND, I covenant with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by me, and that full right to convey the same as herein expressed is possessed by me.

Page 2 of 6

### B. DECLARATION (37 CFR 1.63)

As a below named inventor, I hereby declare that:

This declaration is directed to the patent application entitled:

## MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF; and

Office	; or	attached hereto or prepared for filing in the United States Patent and Trademark
States	⊠ Patent a	identified by United States Application Serial No. 14/448,578 filed in the United and Trademark Office on July 31, 2014; or
		identified by International Patent Application No. Serial No. filed on Filing Date.
	The ab	ove-identified application was made or authorized to be made by me.
invent		ve that I am the original inventor or an original joint inventor of a claimed application.
punish both.		by acknowledge that any willful false statement made in this declaration is der 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or

I have reviewed and understand the contents of the application, including the claims and am aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Page 3 of 6

6235068v1 2007878-0433

KwamphuLu	Oct. 15,201
Name: Kwangho Lee	Date
Witness Signature: Samy jun had	Oct., 15, 2014
Name (please print): Sangjun Park	Date
Witness Signature:	
Lieu See	Oct. 15, 2014
Name (please print): T- T 1	Date

SIGNED this <u>QQ-th</u> day of <u>Nov</u>	ember, 2d F.
	Name: Deqiang Niu
STATE OF	······································
COUNTY OF	SS.
PLOIMAG NIV , and proved to s was <u>ONVUS HUME</u> to be the po	
	NOTARY PUBLIC
	Name: /e/\am* lelus My Commission Expires: \(\lambda \lambda / \frac{1}{2} \rangle \frac{1}{2} \rangle 1 \
	GEOVANNE COLON NOTOTY PUBLIC COMMONWEALTHOF MASSACHUSETTS MY Commission Expires October 27, 2017

SIGNED this 14 day of MA	PCH, 2015.
	Name: Matthew F. Baevsky
STATE OF MASSACHUSE	TIS
COUNTY OF WORCEST	SS.
Before me this 14 day of March appeared Mathew C. Baevs and privers Lic to be or attached document, and acknowledged the and for the purposes set forth	_, 20_15_, Matthew F. Baevsky personally oved to me through satisfactory evidence of identity the person whose name is signed on the preceding at he/she executed the same, of his/her own free will
	NOTARY PUBLIC Name: France Modes
	Name: Steeph MOSES My Commission Expires: May 16, 2019.
	OSEPA MOSES  Notary Public. Commonwealth of Massachusetts My Commission Expires May 16, 2019

**RECORDED: 04/12/2016**